The U.S. FDA has cleared Zymeworks Inc.’s IND application for ZW-251, a novel glypican-3 (GPC3)-targeted antibody-drug conjugate (ADC) incorporating the company’s proprietary topoisomerase 1 (TOPO1) inhibitor payload, ZD-06519, for the treatment of hepatocellular carcinoma (HCC).
Thoracic aortic dissection can progress to a highly lethal cardiac emergency, but it cannot usually be detected in early stages, so suitable biomarkers of progression are needed. Levels of C-reactive protein in serum rise during progression, but they also rise in infectious or autoimmune conditions, making the biomarker nonspecific.
Researchers at the Fred Hutchinson Cancer Research Center found that autoantibodies targeting the exoproteome reshaped checkpoint inhibitor responses and opened new avenues to enhance immunotherapy. In the study published in the July 23, 2025, issue of Nature, the authors set out to address a long-standing question in cancer immunotherapy: why patients with the same type of cancer, treated with the same immunotherapy, can experience such drastically different outcomes.
China Resources Pharmaceutical Research Institute (Shenzhen) Co. Ltd. has prepared and tested Myt1 kinase (PKMYT1) inhibitors reported to be useful for the treatment of cancer.
Cytosinlab Therapeutics Co. Ltd. has synthesized G/T mismatch-specific thymine DNA glycosylase (TDG) inhibitors reported to be useful for the treatment of cancer.
Zenyaku Kogyo Co. Ltd. has identified myosin light chain kinase family member 4 (MYLK4; SGK085) inhibitors reported to be useful for the treatment of arteriosclerosis, inflammatory bowel disease, osteosarcoma, glaucoma, ocular hypertension, dry eye, uveitis and age-related macular degeneration, among others.
Dewpoint Therapeutics Inc. has described TAR DNA-binding protein 43 (TARDBP; TDP-43) modulators reported to be useful for the treatment of traumatic brain injury, frontotemporal dementia and amyotrophic lateral sclerosis.
Ischemic retinopathy refers to a group of ocular disorders characterized by insufficient retinal blood flow, leading to hypoxia and subsequent retinal tissue damage. In the hypoxic environment, hypoxia-inducible factor 1α (HIF-1α) activates the transcription of pro-angiogenic factors that promote pathological retinal neovascularization, which ultimately contributes to edema, retinal damage and vision loss.
Stroke is the third leading cause of disability worldwide, and its incidence is expected to increase as the global population ages. Idebenone can promote recovery after stroke, but it is less effective during the acute phase of stroke.
RSS
